Dementia Matters7 Juli 2023

Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment

On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb), the first medicine shown to delay the course of the disease. Having gone through a rigorous approval process, the medication exemplifies a critical advancement in the ongoing battle to treat Alzheimer’s disease. Having already prescribed the treatment to real-life patients, Dr. Robert Przybelski joins the podcast to discuss his experience prescribing and administering lecanemab, what clinicians and patients should discuss when considering these treatments, and what is needed to integrate these treatments into the healthcare system.

Guest: Robert Przybelski, MD, MS, director, Geriatric Memory Clinics, UW Health, professor, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health

Show Notes

Read more about Lecanemab’s Appropriate Use Guidelines on our website.

Read the FDA’s press release, “FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval.”

Listen to previous Dementia Matters episodes on lecanemab, “Introducing Lecanemab, The Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval,” and “A Closer Look at the Lecanemab Clinical Trials,” on our website and all major podcast platforms.

Listen to Dr. Przybelski’s previous episode of Dementia Matters, “Vitamin Deficiency And Its Impact On Brain Health,” on our website, Spotify, Apple Podcasts, Podbean, and all major podcast platforms.

Connect with us

Find transcripts and more at our website.

Email Dementia Matters: dementiamatters@medicine.wisc.edu

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(244)

New Alzheimer’s Association Special Report Breaks Down How Americans Understand and Support their Brain Health

In recent years, public interest in brain health has increased. So how are Americans understanding brain health information and incorporating it into their own lives? This year, the Alzheimer’s Associ...

25 Aug 37min

Reflecting on 25 Years of the Wisconsin Registry for Alzheimer’s Prevention

Twenty-five years ago, a single participant enrolled in what would become the Wisconsin Registry for Alzheimer's Prevention (WRAP), now one of the largest and longest-running studies of Alzheimer's ri...

12 Aug 35min

How Dementia Caregiving Affects the Spousal Caregiver

Caring for those with dementia represents a major public health challenge, with caregivers, especially spouses, providing long-term, largely unpaid care. With caregiving stress linked to a decline in ...

28 Juli 39min

Managing the Medicine Cabinet: How Prescriptions Impact Cognition and Brain Health as We Age

Prescription medications, over-the-counter drugs and supplements are incredibly common among older adults, yet many of these routine treatments can unexpectedly impact cognitive function and brain hea...

14 Juli 35min

Taking a Deep Dive into Subjective Cognitive Decline

Dr. Jessen returns to the podcast to take a deeper dive into subjective cognitive decline (SCD). Aiming to cover everything relating to SCD, Dr. Jessen shares insights in prognosis, risk factors and h...

7 Juli 17min

Defining Subjective Cognitive Decline

Subjective cognitive decline (SCD) can be one of the earliest noticeable signs of Alzheimer's disease, yet SCD is not yet fully understood. To help us understand more, Dr. Frank Jessen, an expert in t...

30 Juni 30min

SPRINT to a Healthy Mind: How Blood Pressure Control Affects Brain Health and Dementia Risk

Geriatrician Dr. Mark Supiano joins the podcast to discuss the connection between heart and brain health. Citing multiple clinical trials, he breaks down what these studies and their findings mean for...

18 Juni 40min

Addressing Cochrane’s Review on Amyloid-Targeting Treatments for Alzheimer’s Disease

Amyloid-targeting monoclonal antibody treatments have ushered in a new era of Alzheimer’s disease therapies after decades of research and clinical trials. A recent review published by Cochrane, a glob...

4 Juni 44min